Recce Pharmaceuticals Granted New Patent in Israel for RECCE Anti-Infectives - Seite 3

Recce wholly owns its automated manufacturing, which is supporting present clinical trials. Recce’s anti-infective pipeline seeks to exploit the unique capabilities of its technologies targeting synergistic, unmet medical needs.

Corporate Contact
James Graham
Recce Pharmaceuticals Ltd
[phone]
[e-mail]

Media & Investor Relations (AU)
Andrew Geddes
CityPR
[phone]
[e-mail]

Media (USA)
Michael Fitzhugh
LifeSci Communications
[e-mail]

Investor Relations (USA & EU)
Guillame van Renterghem
LifeSci Advisors
[e-mail]

---

¹ World Bank data
² Israel Pharmaceuticals Report – Q42023, Fitch Solutions Group Limited, London